Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

191 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-05-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study will document to what extent in daily clinical practice Humira (adalimumab) therapy is continued, interrupted or permanently discontinued during a follow-up period of 2 years. Reasons for interrupting or permanently discontinuing Humira therapy and reasons for restarting Humira therapy will be noted. An evaluation will be performed of the effect of the disease on quality of life and work productivity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

NCT00735787

Psoriasis

COMPLETED PHASE4

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02850965

Psoriasis

COMPLETED PHASE3

Chronic Plaque Psoriasis (Ps) Registry

NCT00799877

Chronic Plaque Psoriasis

COMPLETED

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

NCT02581345

Chronic Plaque Psoriasis Psoriasis

COMPLETED PHASE3

Documentation of Humira in Psoriasis Patients in Routine Clinical Practice

NCT01077232

Moderate to Severe Plaque Psoriasis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants Treated with Adalimumab

Participants with chronic plaque psoriasis in whom adalimumab (Humira) treatment is initiated. All medications will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients \> or = 18 years
* Patient with chronic plaque psoriasis
* Patient newly initiated on Humira
* Patient compliant with Humira Summary of Product Characteristics
* Patient compliant with Belgian reimbursement criteria of Humira in plaque psoriasis
* Patient has signed informed consent

Exclusion Criteria

* Patients having any of the contraindications mentioned in the Summary of Product Characteristics Humira
* Patients not willing to sign informed consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No